Are all APL screated equal? Background image removed due to copyright considerations.

Slides:



Advertisements
Similar presentations
Acute Promyelocytic Leukemia
Advertisements

3 Aging 1950 ’ s – Believed that cultivated cells could grow forever If not, then it was a result of a culturing deficiency – In 1943, a cancer cell.
Retinoic Acid Receptor- Alpha and Its Role in Acute Promyelocytic Leukemia By Alex Sheng.
27803::Systems Biology1CBS, Department of Systems Biology Schedule for the Afternoon 13:00 – 13:30ChIP-chip lecture 13:30 – 14:30Exercise 14:30 – 14:45Break.
Schedule for the Afternoon 13:00 – 13:30ChIP-chip lecture 13:30 – 14:30Exercise 14:30 – 14:45Break 14:45 – 15:15Regulatory pathways lecture 15:15 – 15:45Exercise.
Dazl shRNA construct design Dann C T et al. PNAS 2006;103: ©2006 by National Academy of Sciences.
Introduction to Hierarchical Clustering Analysis Pengyu Hong 09/16/2005.
Retinoic Acid Receptor Alpha (RARα) Acute Promyelocytic Leukemia (APL)
Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
The Myc Transcription Factor
Redox Proteomics of Oxidative Stress-Induced Cell Death Haiteng Deng.
Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
Molecular Medicine Dr Catherine Flynn Consultant Haematologist St James’s Hospital October 22 nd 2009.
Copyright © 2010, Research To Practice, All rights reserved. Angiogenesis Pathways to Progress? Kathy D Miller, MD Sheila D Ward Scholar of Medicine Associate.
Supplemental Figures. Supplemental Figure 1. Top two canonical pathways clustering the potential predictive biomarkers. The Ingenuity IPA tool was used.
Acute promyelocytic leukemia (APL) From the worst to the best prognosis MUDr. Petr Pavlíček Internal Hematological Clinics FNKV and 3LF UK in Prague.
Causes and consequences of microRNA dysregulation in cancer
BRG-1 in Cancer BRG-1 is an ATPase subunit of the SWI/SNF class of chromatin remodeling complexes It has been found mutated in a number of cancer cell.
Retinoic Acid Receptor-α (RARα) & its role in Acute Promyelocytic Leukemia (APL) Danielle Matsushima.
Telomerase, Immortalization and Cancer Eric Bankaitis Cancer Bio 169 March 9, 2006 Fig.[9]
Prof. Yechiam Yemini (YY) Computer Science Department Columbia University (c)Copyrights; Yechiam Yemini; Lecture 2: Introduction to Paradigms 2.3.
Intro to current collaboration project Why type 2 diabetes? Overview of glucose metabolism and OXPHOS Discussion of Mootha et. al Nature Genetics, 2003.
TSC1 and Facial Angiofibromas
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
Molecular Pathophysiology Musculoskeletal disorders – III Marie Kveiborg.
Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Myeloid Leukemia
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Myeloid Leukemia
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease
Figure 3 Intracranial targeting of high-grade gliomas
About Retinoids Dietary vitamin A—retinol—retinoic acid (RA).
Nat. Rev. Endocrinol. doi: /nrendo
Polydactyly L.A. Lettice, et al. Proc. Natl. Acad. Sci. USA 2002; 99(11):
Relationship between Genotype and Phenotype
Schedule for the Afternoon
D.P. Bartel Cell 136. Faller and Guo BBA 1779.
The 3D models in part a are reproduced with permission from Daum, B
Lessons taught by acute promyelocytic leukemia cure
Identification of genes associated with a gain of prion susceptibility Increased susceptibilities of revertant cell clones R2, R5 and R7 after retinoic.
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
Volume 6, Issue 5, Pages (November 2002)
Chemical Genetic Screening Approaches to Neurobiology
Molecular and genetic basis of β2 -adrenergic receptor function
A New FOXO Pathway Required for Leukemogenesis
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment
Size Control in Animal Development
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.
Colonization in tumor models and different modes of administration
Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.
Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.
Fig. 1. Detection of circulating tumor DNA in CRPC patients.
Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,
Maria Hodges, Catherine Tissot, Kathy Howe, David Grimwade, Paul S
by Dezhi Kang, Baochen Shi, Marie C. Erfe, Noah Craft, and Huiying Li
PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models
Fig. 4 Adenosine A2BR signaling promote osteogenic and inhibit osteoclast differentiation in vitro. Adenosine A2BR signaling promote osteogenic and inhibit.
The Tribble with APL: A New Road to Therapy
SY-1425 shows similar response in RARA-high AML cell lines to APL
Preclinical trials in mouse models of APL
Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR
Fig. 3. Association between peak CTL019 expansion and response.
Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.
PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model
Presentation transcript:

Are all APL screated equal? Background image removed due to copyright considerations.

Background RARαtranslocations in acute promyelocyticleukemia (APL) Mouse models recapitulate the human phenotype Current treatments utilize retinoic acid (RA) to induce differentiation and arsenic trioxide to induce apoptosis Human patients have variable response to therapy

Retinoic acid (RA) and As2O3treatment in transgenic models of acute promyelocyticleukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARαand PLZF-RARαoncoproteins EduaroM. Rego, Li-Zhen He, Raymond P. Warrell, Jr., Zhu-Gang Wang, and Pier Paolo Pandolfi Proc. Natl. Acad. Sci. USA97,

Fig. 1. Effects of treatment with As2O3, RA, or As2O3 + RA on the survival of leukemicTM PML-RAR[alpha] and PLZF-RAR[alpha] Rego,E. M., et al. "Retinoic Acid (RA) and As2O3 Treatment in Transgenic Models of Acute PromyelocyticLeukemia(APL) Unravel the Distinct Nature of the LeukemogenicProcess induced by the PML-RARalphaand PLZF-RARalphaOncoproteins." PNAS 97, no. 18 (August 29, 2000): Copyright 2000 National Academy of Sciences, U.S.A. Used with permission.

Questions remaining: What are the inherent differences/similarities between PML- RARαand PLZF-RARαat the molecular level? How/why does PLZF-RARαrespond differently to RA? Is expression of PLZF-RARαrequired for tumor maintenance?

What are the inherent differences between PML-RARaand PLZF-RARaat the molecular level? Gene expression analysis on random APLsfrom humans followed by identification of the fusion gene Correlate gene expression in PML- RARαvs. PLZF-RARαvs. normal myeloid cells Image removed due to copyright considerations.

Possible results: Common genetic pathways upregulated

How/why does PLZF-RARarespond differently to RA? Additional analysis of gene expression profiles generated in previous section. New gene expression analysis comparing cultured PML-RARα± RA and PLZF- RARα± RA.

Possible results: Inhibition of Hox signaling Image removed due to copyright considerations. *: HoxB3 inhibits differentiation →normal & PML do not express B3 *: HoxD4 promotes differentiation →PLZF does not express D4 or B4

Is expression of PLZF-RARarequired for tumor maintenance? Tetracycline-regulated transgenic expression

Possible results